Farrow Jeffrey S 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) CFO Jeffrey S. Farrow Sells Shares
What Happened
Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (TARS), sold a total of 6,430 shares in three open-market transactions to cover tax withholding tied to vested Restricted Stock Units (RSUs). The sales occurred 3/17–3/19/2026 at the following prices and proceeds: 2,111 shares @ $69.42 = $146,546; 2,133 shares @ $68.71 = $146,558; 2,186 shares @ $67.00 = $146,462. Total proceeds were about $439,566. These were sales (not purchases) executed as part of a mandatory "sell to cover" for taxes, not discretionary trades.
Key Details
- Transaction dates and prices: 2026-03-17 (2,111 @ $69.42), 2026-03-18 (2,133 @ $68.71), 2026-03-19 (2,186 @ $67.00).
- Total shares sold: 6,430; total proceeds: ~$439,566.
- Shares owned after transaction: Not specified in this filing.
- Footnote: Sale was to satisfy tax withholding on RSU vesting per issuer-mandated "sell to cover" (not a discretionary sale by the reporting person).
- Filing timeliness: Form 4 filed 2026-03-19; transactions reported within required filing window (timely).
Context
These transactions were tax-withholding sales tied to RSU settlement — a routine administrative step common when awards vest. Such "sell to cover" transactions are not typically interpreted as an insider expressing a view on the company's stock price.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-17$69.42/sh−2,111$146,546→ 47,635 total - Sale
Common Stock
[F1]2026-03-18$68.71/sh−2,133$146,558→ 45,502 total - Sale
Common Stock
[F1]2026-03-19$67.00/sh−2,186$146,462→ 43,316 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.